Lead-it-EAZY! GMP-compliant production of [²¹²Pb]Pb-PSC-PEG₂-TOC.

ABSTRACT:

Background

Recently, radiotheranostics comprising the true matched radionuclide pair ^203/212Pb could serve as real dosimetric planning utility using ²⁰³Pb-radiolabelled pharmaceuticals before therapy with ²¹²Pb-radiolabelled counterparts. ²¹²Pb might act as the missing radionuclide therapy between standard β^- therapies (e.g. with ¹⁷⁷Lu or ⁹⁰Y), in some cases leading to β^- resistance and highly cytotoxic α therapies (e.g. with ²²⁵Ac) leading in some cases to renal insufficiency or even renal failure, due to the daughter nuclide ²¹³Bi, which accumulates in > 90% within the kidneys during ²²⁵Ac therapy. ²¹²Pb converts to ²¹²Bi by β^--

SUBMITTER: Pretze M 

PROVIDER: S-EPMC11602913 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature